This protocol covers the treatment of solid papillary carcinoma of the breast with evidence of invasion in a specific population: pre-menopausal women whose tumour is oestrogen receptor (ER) positive.
All patients with ER positive disease should receive endocrine therapy. Pre-menopausal status further shapes the approach, as hormonal factors remain active and must be addressed in the treatment plan.
The cornerstone of management in this population is endocrine (hormone-based) therapy, given over an extended duration. For certain pre-menopausal women, ovarian suppression or ablation may be considered as an additional measure alongside the primary endocrine treatment.
The complete regimen — including which patients qualify for each component, the full sequence, and all supporting criteria — is available in the structured protocol below.